Weltman J K
Department of Medicine, Brown University School of Medicine, Providence, Rhode Island, USA.
Allergy Asthma Proc. 1999 Jul-Aug;20(4):255-60. doi: 10.2500/108854199778339071.
Inhaled corticosteroids are the most important therapeutic agents for the pharmacological control of pulmonary inflammation in asthma. There is concern, however, about the occurrence of side effects with the long-term use of inhaled corticosteroids. Because of the potential seriousness of some of these side effects, patients should be monitored carefully and preventively treated for the side effects. Various noncorticosteroid medications have been recommended in guidelines as substitutes for inhaled corticosteroids for daily use as long-term controllers in asthma, e.g., sustained-release theophylline, long-acting beta-agonists, leukotriene modifiers, cromolyn, and nedocromil. However, of the long-term controller medications recommended in the guidelines, only inhaled corticosteroids have to date, been shown clinically to reduce asthma fatalities and to prevent asthma induced lung remodeling.
吸入性糖皮质激素是哮喘肺部炎症药物控制中最重要的治疗药物。然而,人们担心长期使用吸入性糖皮质激素会出现副作用。由于其中一些副作用可能很严重,应对患者进行仔细监测并对副作用进行预防性治疗。在哮喘指南中,已推荐各种非糖皮质激素药物作为吸入性糖皮质激素的替代品,用于日常长期控制,例如缓释茶碱、长效β受体激动剂、白三烯调节剂、色甘酸钠和奈多罗米。然而,在指南推荐的长期控制药物中,迄今为止,只有吸入性糖皮质激素在临床上被证明可降低哮喘死亡率并预防哮喘引起的肺重塑。